CRAYVALLAC® SLX

1. PRODUCT AND COMPANY IDENTIFICATION

Company

Arkema Inc.
900 First Avenue
King of Prussia, Pennsylvania 19406

Arkema Coating Resins

Customer Service Telephone Number: (877) 331-6696
(Monday through Friday, 8:00 AM to 5:00 PM EST)

Emergency Information

Transportation: CHEMTREC: (800) 424-9300
(24 hrs., 7 days a week)
Medical: Rocky Mountain Poison Center: (866) 767-5089
(24 hrs., 7 days a week)

Product Information

Product name: CRAYVALLAC® SLX
Synonyms: Not available
Molecular formula: Complex mixture
Chemical family: Micronized wax
Product use: Additive for :, Paints, Coatings, Inks, Adhesives

2. HAZARDS IDENTIFICATION

Emergency Overview

Color: off-white
Physical state: solid
Form: powder
Odor: odourless

***Classification of the substance or mixture:**
Not a hazardous substance or mixture.

GHS-Labelling

Not a hazardous substance or mixture.

Supplemental information:

Potential Health Effects:
The product, in the form supplied, is not anticipated to produce significant adverse human health effects.

Other:
Handle in accordance with good industrial hygiene and safety practice.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS-No.	Wt/Wt	GHS Classification**
Micronized wax	Proprietary*	<= 100 %	Not classified

*The specific chemical identity is withheld because it is trade secret information of Arkema Inc.

**For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1. Description of necessary first-aid measures:

Inhalation:
If inhaled, remove victim to fresh air.

Skin:
In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing before reuse. Thoroughly clean shoes before reuse.

Eyes:
Immediately flush eye(s) with plenty of water.

Ingestion:
If swallowed, DO NOT induce vomiting. Get medical attention. Never give anything by mouth to an unconscious person.

4.2. Most important symptoms/effects, acute and delayed:

For most important symptoms and effects (acute and delayed), see Section 2 (Hazard Statements and Supplemental Information if applicable) and Section 11 (Toxicology Information) of this SDS.

4.3. Indication of immediate medical attention and special treatment needed, if necessary:

Unless otherwise noted in Notes to Physician, no specific treatment noted; treat symptomatically.

5. FIREFIGHTING MEASURES

Extinguishing media (suitable):
Water spray, Carbon dioxide (CO2), Foam, Dry chemical

Protective equipment:
Fire fighters and others who may be exposed to products of combustion should wear full fire fighting turn out gear (full Bunker Gear) and self-contained breathing apparatus (pressure demand / NIOSH approved or equivalent).

Further firefighting advice:
Fire fighting equipment should be thoroughly decontaminated after use.

Fire and explosion hazards:
When burned, the following hazardous products of combustion can occur:
Carbon oxides
Hazardous organic compounds
Nitrogen oxides

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, Emergency procedures, Methods and materials for containment/clean-up:
Prevent further leakage or spillage if you can do so without risk. Ventilate the area. Avoid dust formation and dispersal of dust in the air. Sweep or scoop up using non-sparking tools and place into suitable properly labeled containers for prompt disposal. The sweepings should be wetted down further with water. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Consult a regulatory specialist to determine appropriate state or local reporting requirements, for assistance in waste characterization and/or hazardous waste disposal and other requirements listed in pertinent environmental permits.

Protective equipment:
Appropriate personal protective equipment is set forth in Section 8.

7. HANDLING AND STORAGE

Handling

General information on handling:
Handle in accordance with good industrial hygiene and safety practices. These practices include avoiding unnecessary exposure and removal of material from eyes, skin, and clothing.

Storage

General information on storage conditions:
This material is not hazardous under normal storage conditions; however, material should be stored in closed containers, in a secure area to prevent container damage and subsequent spillage.

Storage stability – Remarks:
Stable under recommended storage conditions.

Storage incompatibility – General:
Store separate from:
Acids
Oxidizers.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Airborne Exposure Guidelines:

Engineering controls:
Investigate engineering techniques to reduce exposures below airborne exposure limits or to otherwise reduce exposures. Provide ventilation if necessary to minimize exposures or to control exposure levels to below airborne exposure limits (if applicable see above). If practical, use local mechanical exhaust ventilation at sources of air contamination such as open process equipment.

Respiratory protection:
Where airborne exposure is likely or airborne exposure limits are exceeded (if applicable, see above), use NIOSH approved respiratory protection equipment appropriate to the material and/or its components. Consult respirator manufacturer to determine appropriate type equipment for a given application. Observe respirator use limitations specified by NIOSH or the manufacturer. For emergency and other conditions where there may be a potential for significant exposure or where exposure limit may be significantly exceeded, use an approved full face positive-pressure, self-contained breathing apparatus or positive-pressure airline with auxiliary self-contained air supply. Respiratory protection programs must comply with 29 CFR § 1910.134.

Skin protection:
Minimize skin contamination by following good industrial hygiene practice. Wearing protective gloves is recommended. Wash hands and contaminated skin thoroughly after handling.

Eye protection:
Use good industrial practice to avoid eye contact.

9. PHYSICAL AND CHEMICAL PROPERTIES

Color:	off-white
Physical state:	solid
Form:	powder
Odor:	odourless
Odor threshold:	No data available
Flash point	No data available
Auto-ignition temperature:	> 752 °F (400 °C)

Lower flammable limit (LFL):	No data available
Upper flammable limit (UFL):	No data available
pH:	No data available
Density:	0.929 g/cm3 (68 °F (20 °C)) (Method: OECD Test Guideline 109)
Specific Gravity (Relative density):	0.929 (68 °F(20 °C))Water=1 (liquid)
Boiling point/boiling range:	>= 482 °F (250 °C) (Method: OECD Test Guideline 103)
Melting point/range:	between 243 - 261 °F (117 - 127 °C)(Method: OECD Test Guideline 102)
Freezing point:	No data available.
Evaporation rate:	No data available
Solubility in water:	insoluble
Viscosity, dynamic:	No data available
Particle size:	D10 : 1.8 µm D90 : 15 µm
Oil/water partition coefficient:	(No data available)
Thermal decomposition:	>= 482 °F (250 °C)
Flammability:	See GHS Classification in Section 2 if applicable

10. STABILITY AND REACTIVITY

Stability:
This material is chemically stable under normal and anticipated storage, handling and processing conditions.

Hazardous reactions:
Hazardous polymerization does not occur.

Materials to avoid:
Acids
Oxidizers.

Conditions / hazards to avoid:
Keep away from heat and sources of ignition.

Hazardous decomposition products:

Thermal decomposition giving flammable and toxic products
Carbon oxides
Nitrogen oxides
Hazardous organic compounds

11. TOXICOLOGICAL INFORMATION

Data for CRAYVALLAC® SLX

Acute toxicity

Oral:
No deaths occurred. (rat) LD0 > 2,000 mg/kg.

Dermal:
No deaths occurred. (rat) LD0 > 2,000 mg/kg.

Inhalation:
Practically nontoxic. (rat) 4 h LC0 > 5.11 mg/l. (dust)

Skin Irritation:
Practically non-irritating. (rabbit) (4 h)

Eye Irritation:
Causes mild eye irritation. (rabbit)

Skin Sensitization:
Not a sensitizer. LLNA: Local Lymph Node Assay. (mouse) No skin allergy was observed.

Repeated dose toxicity
Repeated inhalation administration to rat / affected organ(s): Respiratory Tract / signs: irritation

Genotoxicity

Assessment in Vitro:
No genetic changes were observed in laboratory tests using: bacteria, animal cells, human cells

Developmental toxicity
Reproductive/Developmental Effects Screening Assay. oral (rat) / No birth defects were observed.

Reproductive effects

Reproductive/Developmental Effects Screening Assay. oral (rat) / No toxicity to reproduction.

Other information
The information presented is from representative materials in this chemical class. The results may vary depending on the test substance.

12. ECOLOGICAL INFORMATION

Chemical Fate and Pathway

Data for CRAYVALLAC® SLX

Biodegradation:
Readily biodegradable. (28 d) biodegradation 63 %

Octanol Water Partition Coefficient:
log Pow: > 6, at 77 °F (25 °C)

Ecotoxicology

Data for CRAYVALLAC® SLX

Aquatic toxicity data:
No effect up to the limit of solubility. Oncorhynchus mykiss (rainbow trout) 96 h LC50 > 100 mg/l (Nominal concentration, Water accommodated fraction was tested.)

Aquatic invertebrates:
Harmful. Daphnia magna (Water flea) 48 h EL50 94.9 mg/l (nominal concentrations reported, Water accommodated fraction was tested.)

Algae:
Harmful. Pseudokirchneriella subcapitata (green algae) 72 h EL50 = 43.2 mg/l (nominal concentrations reported, Water accommodated fraction was tested.)

Microorganisms:
Respiration inhibition / Activated sludge 3 h EC50 > 1,000 mg/l (nominal concentrations reported)

Chronic toxicity to aquatic invertebrates:
Practically nontoxic. Daphnia magna (Water flea) 21 d NOELR (reproduction) > 20 mg/l (Nominal concentration Water accommodated fraction was tested.)

Chronic toxicity to aquatic plants:
Practically nontoxic. Pseudokirchneriella subcapitata (green algae) 72 h NOEC (growth rate) = 20.7 mg/l (Nominal concentration)

13. DISPOSAL CONSIDERATIONS

Waste disposal:
Where possible recycling is preferred to disposal or incineration. If recycling is not an option, incinerate or dispose of in accordance with federal, state, and local regulations. Consult a regulatory specialist to determine appropriate state or local reporting requirements, for assistance in waste characterization and/or hazardous waste disposal and other requirements listed in pertinent environmental permits. Note: Chemical additions to, processing of, or otherwise altering this material may make this waste management information incomplete, inaccurate, or otherwise inappropriate. Furthermore, state and local waste disposal requirements may be more restrictive or otherwise different from federal laws and regulations.

14. TRANSPORT INFORMATION

US Department of Transportation (DOT): not regulated

International Maritime Dangerous Goods Code (IMDG): not regulated

15. REGULATORY INFORMATION

Chemical Inventory Status

US. Toxic Substances Control Act	TSCA	The components of this product are all on the TSCA Inventory.
Canadian Domestic Substances List (DSL)	DSL	All components of this product are on the Canadian DSL
China. Inventory of Existing Chemical Substances in China (IECSC)	IECSC (CN)	Does not conform
Japan. ENCS - Existing and New Chemical Substances Inventory	ENCS (JP)	Does not conform
Japan. ISHL - Inventory of Chemical Substances	ISHL (JP)	Does not conform
Korea. Korean Existing Chemicals Inventory (KECI)	KECI (KR)	Conforms to
Australia Inventory of Chemical Substances (AICS)	AICS	Conforms to
Philippines Inventory of Chemicals and Chemical Substances (PICCS)	PICCS (PH)	Does not conform

United States – Federal Regulations

SARA Title III – Section 302 Extremely Hazardous Chemicals:
The components in this product are either not SARA Section 302 regulated or regulated but present in negligible concentrations.

SARA Title III - Section 311/312 Hazard Categories:
No SARA Hazards

SARA Title III – Section 313 Toxic Chemicals:
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) - Reportable Quantity (RQ):

The components in this product are either not CERCLA regulated, regulated but present in negligible concentrations, or regulated with no assigned reportable quantity.

United States – State Regulations

New Jersey Right to Know

No components are subject to the New Jersey Right to Know Act.

Pennsylvania Right to Know

Chemical name	CAS-No.
Micronized wax	Proprietary

California Prop. 65
This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive defects.

16. OTHER INFORMATION

Latest Revision(s):

Reference number:	200002475
Date of Revision:	03/02/2020
Date Printed:	03/02/2020

CRAYVALLAC® is a registered trademark of Arkema Inc.

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; **NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN.** The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html) Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices , and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.
It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.